{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:46:14Z","timestamp":1789562774345,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-3852-3","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T14:04:11Z","timestamp":1551967451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Magnitude and correlates of virological failure among adult HIV patients receiving PI based second line ART regimens in north western Tanzania; a case control study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2701-9321","authenticated-orcid":false,"given":"Daniel W.","family":"Gunda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semvua B.","family":"Kilonzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarcisius","family":"Mtaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desderius M.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samwel E.","family":"Kalluvya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elichilia R.","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"issue":"3","key":"3852_CR1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1086\/499313","volume":"193","author":"J Todd","year":"2006","unstructured":"Todd J, et al. Risk factors influencing HIV infection incidence in a rural African population: a nested case-control study. J Infect Dis. 2006;193(3):458\u201366.","journal-title":"J Infect Dis"},{"issue":"16","key":"3852_CR2","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/QAD.0b013e32830f97e2","volume":"22","author":"ML Petersen","year":"2008","unstructured":"Petersen ML, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS. 2008;22(16):2097\u2013106.","journal-title":"AIDS"},{"issue":"3","key":"3852_CR3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1086\/600396","volume":"49","author":"R Kantor","year":"2009","unstructured":"Kantor R, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis. 2009;49(3):454\u201362.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3852_CR4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017518","volume":"6","author":"Z El-Khatib","year":"2011","unstructured":"El-Khatib Z, et al. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011;6(3):e17518.","journal-title":"PLoS One"},{"issue":"7","key":"3852_CR5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021795","volume":"6","author":"PC Mutevedzi","year":"2011","unstructured":"Mutevedzi PC, et al. Association of age with mortality and virological and immunological response to antiretroviral therapy in rural south African adults. PLoS One. 2011;6(7):e21795.","journal-title":"PLoS One"},{"key":"3852_CR6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1758-2652-14-14","volume":"14","author":"L Ferradini","year":"2011","unstructured":"Ferradini L, et al. High efficacy of lopinavir\/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER\/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc. 2011;14:14.","journal-title":"J Int AIDS Soc"},{"issue":"2","key":"3852_CR7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-3156.2010.02689.x","volume":"16","author":"M Pujades-Rodriguez","year":"2011","unstructured":"Pujades-Rodriguez M, et al. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia. Tropical Med Int Health. 2011;16(2):205\u201313.","journal-title":"Tropical Med Int Health"},{"issue":"4","key":"3852_CR8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/2229-3485.120170","volume":"4","author":"D Patel","year":"2013","unstructured":"Patel D, et al. Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients. Perspect Clin Res. 2013;4(4):215\u201320.","journal-title":"Perspect Clin Res"},{"key":"3852_CR9","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.17.1.19164","volume":"17","author":"BE Nichols","year":"2014","unstructured":"Nichols BE, et al. Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study. J Int AIDS Soc. 2014;17:19164.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"3852_CR10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/QAD.0b013e32834e1b5f","volume":"26","author":"T Gsponer","year":"2012","unstructured":"Gsponer T, et al. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. AIDS. 2012;26(1):57\u201365.","journal-title":"AIDS"},{"issue":"4","key":"3852_CR11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/QAI.0b013e3181bcdac1","volume":"53","author":"MP Fox","year":"2010","unstructured":"Fox MP, et al. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010;53(4):500\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3852_CR12","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12879-015-1270-8","volume":"15","author":"J Chakravarty","year":"2015","unstructured":"Chakravarty J, et al. Outcome of patients on second line antiretroviral therapy under programmatic condition in India. BMC Infect Dis. 2015;15:517.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"3852_CR13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/QAI.0b013e31820dc0cc","volume":"56","author":"GU Zyl van","year":"2011","unstructured":"van Zyl GU, et al. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr. 2011;56(4):333\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"3852_CR14","doi-asserted-by":"crossref","first-page":"ofu079","DOI":"10.1093\/ofid\/ofu079","volume":"1","author":"HO Ramadhani","year":"2014","unstructured":"Ramadhani HO, et al. Association of first-line and second-line antiretroviral therapy adherence. Open Forum Infect Dis. 2014;1(2):ofu079.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"3852_CR15","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32833a097b","volume":"24","author":"Z El-Khatib","year":"2010","unstructured":"El-Khatib Z, et al. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010;24(11):1679\u201387.","journal-title":"AIDS"},{"issue":"12","key":"3852_CR16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012537","volume":"6","author":"AT Tsegaye","year":"2016","unstructured":"Tsegaye AT, et al. Predictors of treatment failure on second-line antiretroviral therapy among adults in Northwest Ethiopia: a multicentre retrospective follow-up study. BMJ Open. 2016;6(12):e012537.","journal-title":"BMJ Open"},{"key":"3852_CR17","first-page":"6817325","volume":"2016","author":"CR Ojha","year":"2016","unstructured":"Ojha CR, Shakya G, Dumre SP. Virological and immunological status of the people living with HIV\/AIDS undergoing ART treatment in Nepal. Biomed Res Int. 2016;2016:6817325.","journal-title":"Biomed Res Int"},{"issue":"9","key":"3852_CR18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075118","volume":"8","author":"DW Gunda","year":"2013","unstructured":"Gunda DW, et al. Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-Western Tanzania. PLoS One. 2013;8(9):e75118.","journal-title":"PLoS One"},{"issue":"3","key":"3852_CR19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032144","volume":"7","author":"JH Levison","year":"2012","unstructured":"Levison JH, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One. 2012;7(3):e32144.","journal-title":"PLoS One"},{"issue":"4","key":"3852_CR20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4314\/mmj.v27i4.2","volume":"27","author":"H Mhozya","year":"2015","unstructured":"Mhozya H, et al. Late-stage disease at presentation to an HIV clinic in eastern Tanzania: a retrospective cross-sectional study. Malawi Med J. 2015;27(4):125\u20137.","journal-title":"Malawi Med J"},{"issue":"11","key":"3852_CR21","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/infdis\/jis261","volume":"205","author":"KC Sigaloff","year":"2012","unstructured":"Sigaloff KC, et al. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in sub-Saharan Africa. J Infect Dis. 2012;205(11):1739\u201344.","journal-title":"J Infect Dis"},{"issue":"1","key":"3852_CR22","volume":"10","author":"NTT Kyaw","year":"2017","unstructured":"Kyaw NTT, et al. Long-term outcomes of second-line antiretroviral treatment in an adult and adolescent cohort in Myanmar. Glob Health Action. 2017;10(1):1290916.","journal-title":"Glob Health Action"},{"issue":"8","key":"3852_CR23","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/QAD.0b013e328351f5b2","volume":"26","author":"O Ajose","year":"2012","unstructured":"Ajose O, et al. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012;26(8):929\u201338.","journal-title":"AIDS"},{"issue":"1","key":"3852_CR24","doi-asserted-by":"crossref","DOI":"10.7448\/IAS.20.1.21930","volume":"20","author":"RS Boerma","year":"2017","unstructured":"Boerma RS, et al. Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure. J Int AIDS Soc. 2017;20(1):21930.","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"3852_CR25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023091","volume":"6","author":"C Kasang","year":"2011","unstructured":"Kasang C, et al. HIV drug resistance (HIVDR) in antiretroviral therapy-naive patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. PLoS One. 2011;6(8):e23091.","journal-title":"PLoS One"},{"issue":"7","key":"3852_CR26","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/jac\/dkw051","volume":"71","author":"C Hawkins","year":"2016","unstructured":"Hawkins C, et al. HIV virological failureand drug resistance in a cohort of Tanzanian HIV-infected adults. J Antimicrob Chemother. 2016;71(7):1966\u201374.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"3852_CR27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1186\/s12879-017-2709-x","volume":"17","author":"A Luca De","year":"2017","unstructured":"De Luca A, et al. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique. BMC Infect Dis. 2017;17(1):605.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"3852_CR28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1089\/aid.2011.0136","volume":"28","author":"KC Sigaloff","year":"2012","unstructured":"Sigaloff KC, et al. Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Res Hum Retrovir. 2012;28(2):171\u20135.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"5","key":"3852_CR29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1089\/apc.2016.0291","volume":"31","author":"D Onoya","year":"2017","unstructured":"Onoya D, et al. Predicting the need for third-line antiretroviral therapy by identifying patients at high risk for failing second-line antiretroviral therapy in South Africa. AIDS Patient Care STDs. 2017;31(5):205\u201312.","journal-title":"AIDS Patient Care STDs"},{"key":"3852_CR30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2147\/PPA.S75876","volume":"9","author":"B Tsega","year":"2015","unstructured":"Tsega B, Srikanth BA, Shewamene Z. Determinants of non-adherence to antiretroviral therapy in adult hospitalized patients, Northwest Ethiopia. Patient Prefer Adherence. 2015;9:373\u201380.","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"3852_CR31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/heapol\/czp006","volume":"24","author":"BS Uzochukwu","year":"2009","unstructured":"Uzochukwu BS, et al. Determinants of non-adherence to subsidized anti-retroviral treatment in Southeast Nigeria. Health Policy Plan. 2009;24(3):189\u201396.","journal-title":"Health Policy Plan"},{"issue":"43","key":"3852_CR32","doi-asserted-by":"crossref","first-page":"e1715","DOI":"10.1097\/MD.0000000000001715","volume":"94","author":"VP Thao","year":"2015","unstructured":"Thao VP, et al. Second-line HIV therapy outcomes and determinants of mortality at the largest HIV referral Center in Southern Vietnam. Medicine (Baltimore). 2015;94(43):e1715.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"3852_CR33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/jama.2010.980","volume":"304","author":"M Pujades-Rodriguez","year":"2010","unstructured":"Pujades-Rodriguez M, et al. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA. 2010;304(3):303\u201312.","journal-title":"JAMA"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-3852-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3852-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T04:23:01Z","timestamp":1663042981000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-3852-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3852"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-3852-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"assertion":[{"value":"18 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The permission to conduct and publish the results from this study was sought from the catholic University of Health and allied Sciences\/ Bugando Medical Center joint ethical committee with clearance certificate no 515\/2017. The patient\u2019s files were handled by the researchers alone and the patients\u2019 identifiers including names and registration numbers were not included in the analysis to further maintain confidentiality.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"235"}}